The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but placing funds in companies heavily reliant on off-patent versions presents a challenging picture. Despite early earnings were significant, the end of patents and the rise of less expensive alternatives have eroded market share. Therefore, a thorough assessmen